Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

This is interesting. A few years ago, as part of the worldwide ban on CFCs to protect the ozone layer, CFC-based asthma inhalers were banned. Asthma sufferers everywhere complained about this, because the replacement HFA-based inhalers didn’t work as well. They fingered the culprits as an unholy alliance of idiot bureaucrats and overbearing environmentalists, who banned the inhalers even though their contribution to ozone destruction was minuscule and all other CFC uses had already been eliminated.

I love the ozone layer as much as anyone, but I was sympathetic to the asthma crowd. Thus I was interested to read Nick Baumann’s piece in the current issue of MoJo explaining who was behind the CFC inhaler ban. As it turns out, it wasn’t really environmentalists who made the big push, it was the manufacturers of asthma inhalers:

Pharmaceutical companies, worried about the emergence of generic competition, soon spied an opening. If they could create and patent a new variety of CFC-free inhalers, securing the exclusive rights to sell them, they could force off-brand competitors out of the market and jack up prices.

….The pharma consortium transformed from primarily an R&D outfit searching for substitutes for CFC-based inhalers into a lobbying group intent on eliminating the old inhalers. It set up shop in the K Street offices of Drinker Biddle, a major DC law firm….The lobbying paid off. In 2005, the Food and Drug Administration (FDA) approved an outright ban on many CFC-based inhalers starting in 2009.

….The switch to the new inhalers will cost American consumers, insurance companies, and the government some $8 billion by 2017, according to FDA estimates. That’s money in the drug companies’ pockets. In 2007, a top market-research firm alerted investors that the US inhaler market “will soon change from low-value to significant.” Sure enough, at nearly $1 billion a year, sales of the market-leading inhaler, ProAir, now rival Viagra’s.

Maybe the ban on CFC inhalers would have happened anyway. But even if it did, there was no special reason that it had to wipe out the generic market for asthma inhalers at the same time. So score one for big pharma. By my count, that makes the current score Big Pharma 873, Taxpayers 0.

WE'LL BE BLUNT:

We need to start raising significantly more in donations from our online community of readers, especially from those who read Mother Jones regularly but have never decided to pitch in because you figured others always will. We also need long-time and new donors, everyone, to keep showing up for us.

In "It's Not a Crisis. This Is the New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, how brutal it is to sustain quality journalism right now, what makes Mother Jones different than most of the news out there, and why support from readers is the only thing that keeps us going. Despite the challenges, we're optimistic we can increase the share of online readers who decide to donate—starting with hitting an ambitious $300,000 goal in just three weeks to make sure we can finish our fiscal year break-even in the coming months.

Please learn more about how Mother Jones works and our 47-year history of doing nonprofit journalism that you don't find elsewhere—and help us do it with a donation if you can. We've already cut expenses and hitting our online goal is critical right now.

payment methods

WE'LL BE BLUNT

We need to start raising significantly more in donations from our online community of readers, especially from those who read Mother Jones regularly but have never decided to pitch in because you figured others always will. We also need long-time and new donors, everyone, to keep showing up for us.

In "It's Not a Crisis. This Is the New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, how brutal it is to sustain quality journalism right now, what makes Mother Jones different than most of the news out there, and why support from readers is the only thing that keeps us going. Despite the challenges, we're optimistic we can increase the share of online readers who decide to donate—starting with hitting an ambitious $300,000 goal in just three weeks to make sure we can finish our fiscal year break-even in the coming months.

Please learn more about how Mother Jones works and our 47-year history of doing nonprofit journalism that you don't find elsewhere—and help us do it with a donation if you can. We've already cut expenses and hitting our online goal is critical right now.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate